(New York)

Being journalists ourselves, we are always on the lookout for the best content for our readers, including who to read for stock calls. That led us to a site, called TipRanks, which ranks all the equity research analysts on Wall Street. One of the major components of their rankings is their average market return per recommendation. The top ten analysts from returns are: Richard Davis, Cannacord Genuity (42.7% return per recommendation); Ross MacMillan, RBC Capital; Joseph Foresi, Cantor Fitzgerald; Matthew Hedberg, RBC Capital; Glenn Greene, Oppenheimer; Brian Schwartz, Oppenheimer; John Difucci, Jefferies; Brent Bracelin, KeyBanc; Gerard Cassidy, RBC Capital; and Brian Peterson, Raymond James.


FINSUM: This list, and TipRanks in general, is a great way to separate value from noise in all those equity research comments.

Published in Eq: Total Market
Monday, 18 February 2019 09:43

7 Top Analyst Stock Buys

(New York)

We thought our readers might like to see some high conviction stock buys from top ranking sell-side analysts. All of the following seven picks are rated a “strong buy” by top ranked analysts and have price targets 20% or more above the current price. The picks come from a wide variety of sectors and include: Turtle Beach (HEAR), Alibaba (BABA), Cigna Corp (CI), Marathon Petroleum (MPC), Amarin Corp (AMRN), and Teladoc Health (TDOC).


FINSUM: These are diverse picks both in terms of geography and sector. Amarin and Alibaba are the most interesting for us. The former because of buyout rumors by Pfizer, and the latter because of its strong growth characteristics.

Published in Eq: Value
Monday, 11 February 2019 11:05

The Stock Picker’s Guide to Value

(New York)

Value stocks have been in a slump for a decade, with growth consistently outperforming. That acknowledged, there is still something to be said for buying beaten up stocks, which seem to have less downside than highly valued growth names. But how to do it? Try an old stock picker’s favorite: buy the ten stocks with the highest dividend yields in the Dow, a strategy which has historically performed well and is called the “Dogs of the Dow”. These stocks tend to have great dividend yields, and generally outperform the index as a whole. The bottom ten right now are: Verizon, IBM, Pfizer, Chevron, Exxon-Mobil, Merck, Coca-Cola, Cisco, Procter & Gamble, and JP Morgan.


FINSUM: This sounds like a solid bet, though because of the group, you are buying them with no real catalyst.

Published in Eq: Value
Friday, 08 February 2019 10:38

The Top 20 Analyst Picks for 2019

(New York)

It’s that time of year. Analysts from many banks are putting out their top picks for the year. The picks we are featuring focus mostly on the large cap space. The picks come from a range of different analysts and include: Google, Amazon, American Eagle, Broadcom, Deere, McDonald’s, Microsoft, and Salesforce.


FINSUM: Deere and McDonalds are interesting for us. Deere because farm equipment demand could be quite heavily impacted by US-China trade tensions, which makes this one a risky bet. McDonalds is a stock we are bullish on because of its menu changes and modernization efforts. We think it has a lot of business it can steal back from the likes of Shake Shack and Chipotle if it continues to make its menu fresher and more healthful and its store more appealing.

Published in Eq: Total Market
Thursday, 07 February 2019 08:29

Analysts’ Top Growth Stocks

(New York)

Top Wall Street analysts have just published updated outlooks on the best growth stocks. This piece looks at top ranked analyst recommendations. The top 5 growth stocks for this year are: cloud communications platform Twilio, athletics apparel retailer Lululemon, cloud stock MongoDB, Amazon, and healthcare stock Sarepta Therapeutics.


FINSUM: The big question in growth stocks is whether they will continue to outperform value, as they have for several years. We think the trend is your friend here.

Published in Eq: Growth
Page 1 of 3

Contact Us

Newsletter

Subscribe

Subscribe to our daily newsletter

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…